Last updated on December 2019

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Brief description of study

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Clinical Study Identifier: NCT03222609

Find a site near you

Start Over

University of Utah /ID# 164116

Salt Lake City, UT United States
  Connect »